United States Male Infertility Market to Reach USD 6.62 Billion by 2033 | CAGR 4.9% | North America Leads with 37% Share | Key Players: Merck KGaA, Vitrolife, Ferring Pharmaceuticals, CooperSurgical, Aytu BioPharma

Male Infertility Market Overview:

The Male Infertility Market reached US$ 4.33 billion in 2024 and is projected to reach US$ 6.62 billion by 2033, growing at a CAGR of 4.9% during the forecast period 2025-2033. The global male infertility market is a key segment within the fertility treatment industry, addressing the diagnosis, management, and treatment of male reproductive disorders. Male infertility defined as the inability to achieve conception after 12 months of unprotected intercourse accounts for nearly 40-50% of infertility cases worldwide.

The market encompasses diagnostic testing (hormonal assays, genetic testing, semen analysis), therapeutic interventions (hormonal therapy, antioxidant treatment, varicocele repair), and assisted reproductive technologies (ART) such as intrauterine insemination (IUI) and intracytoplasmic sperm injection (ICSI). Increasing awareness about male reproductive health, the growing prevalence of lifestyle-related disorders (e.g., obesity, smoking, stress), and delayed parenthood trends are contributing to market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/male-infertility-market?Juli

Recent Developments:

✅ October 2025: Irvine Scientific, a part of FUJIFILM Group, launched an advanced sperm processing medium designed to improve sperm motility and viability during assisted reproductive procedures such as ICSI and IVF.

✅ August 2025: Memphasys Ltd. received regulatory approval in multiple markets for its FelixTM device, a novel sperm separation technology that enhances sperm quality and selection efficiency for ART treatments.

✅ May 2025: Ferring Pharmaceuticals introduced an updated gonadotropin therapy formulation to improve hormonal balance and spermatogenesis in men with hypogonadotropic hypogonadism-related infertility.

✅ April 2025: CooperSurgical expanded its reproductive health portfolio with a new AI-powered semen analysis system, capable of automated sperm morphology assessment to improve diagnostic accuracy.

✅ January 2025: Researchers at the University of Copenhagen published groundbreaking findings linking genetic mutations in Y-chromosome microdeletions to idiopathic infertility, paving the way for more precise genetic screening and personalized treatment approaches.

Mergers & Acquisitions:

✅ September 2025: CooperSurgical acquired a leading male fertility diagnostics company specializing in AI-driven sperm analysis tools to strengthen its reproductive technology portfolio.

✅ July 2025: Ferring Pharmaceuticals entered into a strategic partnership with a biotech firm focused on hormonal therapeutics to co-develop next-generation gonadotropin formulations for male infertility treatment.

✅ May 2025: Vitrolife AB completed the acquisition of a European fertility technology startup offering microfluidic-based sperm sorting solutions, enhancing ART efficiency and sperm selection precision.

✅ February 2025: Merck KGaA acquired a reproductive genetics company to integrate genetic testing and biomarker-based diagnostics into its fertility treatment offerings.

✅ December 2024: Irvine Scientific (FUJIFILM Group) announced the acquisition of a reproductive media manufacturer, expanding its global reach and strengthening its ART consumables portfolio.

Key Players:
Aytu BioPharma, Inc. | Cadila Pharmaceuticals | CinnaGen Co. | Vitrolife | Halotech DNA | Merck KGaA | Spermosens AB | Zydus Healthcare Limited | Intas Pharmaceuticals Ltd.

Key Highlights:

• Aytu BioPharma, Inc. - 14% share: Specializes in therapeutics for male sexual and reproductive health, including hormonal and non-hormonal treatments that enhance spermatogenesis and sperm motility.

• Cadila Pharmaceuticals - 12% share: Focuses on fertility-enhancing drugs and hormonal therapies for men with oligospermia and hypogonadism, with a strong presence in emerging markets.

• CinnaGen Co. - 10% share: Engaged in biotechnology-based infertility treatments, including recombinant hormone formulations and biosimilars for gonadotropin therapies.

• Vitrolife - 13% share: A global leader in assisted reproductive technology (ART) solutions, offering advanced sperm processing, cryopreservation, and microfluidic-based selection systems.

• Halotech DNA - 9% share: Specializes in sperm DNA fragmentation and oxidative stress testing kits, supporting accurate diagnosis and treatment planning in fertility clinics.

• Merck KGaA - 15% share: Dominates the hormonal therapy segment, providing gonadotropins, FSH analogs, and integrated fertility diagnostics as part of its global fertility care portfolio.

• Spermosens AB - 8% share: Focuses on sperm function diagnostics, developing innovative biosensor-based platforms for assessing male fertility potential.

• Zydus Healthcare Limited - 10% share: Manufactures and markets male fertility medications and antioxidant therapies aimed at improving sperm quality and count.

• Intas Pharmaceuticals Ltd. - 9% share: Offers andrology-focused medications and research-backed hormonal therapies targeting reproductive dysfunctions and infertility in men.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=male-infertility-market?Juli

Market Segmentation:

By Treatment, Assisted Reproductive Technology (ART) dominates the market with approximately 60% share in 2024, driven by the widespread adoption of advanced reproductive techniques such as Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), and In Vitro Fertilization (IVF). Increasing success rates, technological advancements in sperm selection, and AI-assisted embryo analysis have strengthened ART's role in addressing male infertility. Medication-based treatments account for 40%, primarily comprising hormonal therapies, antioxidants, and lifestyle modification drugs that enhance sperm quality and motility in cases of mild or functional infertility.

By End-User, Fertility Clinics lead the market with 45% share, driven by specialized expertise, advanced diagnostic tools, and integrated ART services. Hospitals hold 35%, offering comprehensive treatment and surgical interventions such as varicocelectomy and hormonal management. Research and Academic Institutes account for 20%, focusing on clinical trials, genetic studies, and the development of next-generation reproductive technologies.

Regional Insights:

North America dominates the global male infertility market with a 37% share (USD 1.60 billion in 2024), driven by advanced healthcare infrastructure, high awareness of reproductive health, and widespread adoption of assisted reproductive technologies (ART). The United States leads the region due to strong clinical research initiatives, presence of major fertility centers, and growing prevalence of lifestyle-related infertility cases.

Europe holds a 30% share (USD 1.30 billion in 2024), supported by government-backed fertility programs, favorable reimbursement policies, and increasing demand for ART and sperm function diagnostics. Countries such as Germany, France, and the UK are investing heavily in fertility innovation, including AI-based semen analysis and DNA fragmentation testing technologies.

Asia-Pacific accounts for 25% (USD 1.08 billion in 2024) and is the fastest-growing region, with a projected CAGR of over 6.5% during 2025-2033. The region's growth is fueled by rising infertility rates, increasing medical tourism, and expanding fertility treatment infrastructure in India, China, Japan, and South Korea. Government initiatives promoting awareness and affordability of fertility care are also driving market expansion.

Latin America, Middle East & Africa (LAMEA) contribute 8% (USD 0.35 billion in 2024), with gradual market growth supported by improved access to reproductive healthcare and expanding ART clinics in Brazil, Mexico, the UAE, and South Africa. Increasing awareness of male reproductive health and adoption of advanced diagnostic techniques are strengthening the region's fertility landscape.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/male-infertility-market?Juli

Market Dynamics:

Drivers
The market is primarily driven by the rising prevalence of male infertility caused by stress, sedentary lifestyles, obesity, smoking, alcohol consumption, and environmental pollution. Increasing awareness of male reproductive health, coupled with advancements in diagnostic technologies such as AI-based semen analysis, DNA fragmentation testing, and genetic screening, is enhancing early detection and treatment accuracy. The growing adoption of assisted reproductive technologies (ART), favorable reimbursement policies in developed countries, and expanding fertility clinics worldwide are also fueling market growth.

Restraints
High treatment costs, limited access to advanced fertility care in developing regions, and social stigma surrounding male infertility remain significant barriers. In addition, the side effects of hormonal therapies and a lack of awareness among men regarding reproductive health can impede timely diagnosis and treatment adoption. Regulatory hurdles related to ART procedures and ethical concerns further limit market penetration in some regions.

Opportunities
Significant opportunities lie in the development of non-invasive diagnostic tools, genetic testing kits, and personalized fertility therapies. The increasing integration of AI, machine learning, and automation in sperm selection and fertility monitoring creates new growth avenues. Expanding medical tourism, especially in countries like India, Thailand, and Turkey, offers cost-effective treatment options, driving cross-border demand for male infertility care.

Trends
The market is witnessing a growing trend toward precision medicine and genomics-based reproductive treatments, enabling personalized fertility solutions. There is also rising interest in sperm cryopreservation and preservation of fertility among cancer patients. Moreover, collaborations between biotech companies and fertility clinics for developing next-generation hormonal therapies and ART innovations are redefining the male infertility treatment landscape.

Key Developments:

✅ April 2025: Illumicell AI, a Boston-based tech-med startup, secured $2 million in pre-seed funding to launch a portable AI-powered lab scanner for fluid-based diagnostics. The company's first product-a real-time sperm analysis scanner-is designed to revolutionize male fertility testing by providing rapid, accurate assessments of sperm health and biomarkers, enhancing accessibility and precision in fertility care.

✅ June 2024: Ferring Pharmaceuticals, in collaboration with Posterity Health, introduced a Male Fertility Program on its Fertility Out Loud platform. The program encourages men to proactively assess their fertility through a confidential online evaluation, offering personalized reproductive health insights and educational content developed by fellowship-trained reproductive urologists.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.